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Pancreatic cancerEpidermal growth factor (EGF)-induced EGFR tyrosine kinase receptor activation in cancer cell survival responses
has become a strategic molecular-targeting clinical therapeutic intent, but the failures of these targeted
approaches in the clinical setting demand alternate strategies. Here, we uncover a novel neuraminidase-1
(Neu1) and matrix metalloproteinase-9 (MMP-9) cross-talk in alliance with GPCR neuromedin B, which is
essential for EGF-induced receptor activation and cellular signaling. Neu1 and MMP-9 form a complex with
EGFR on the cell surface. Tamiﬂu (oseltamivir phosphate), anti-Neu1 antibodies, broad range MMP inhibitor
galardin (GM6001), neuromedin B GPCR speciﬁc antagonist BIM-23127, the selective inhibitor of whole
heterotrimeric G-protein complex BIM-46174 and MMP-9 speciﬁc inhibitor dose-dependently inhibited Neu1
activity associated with EGF stimulated 3T3–hEGFR cells. Tamiﬂu, anti-Neu1 antibodies and MMP9i attenuated
EGFR phosphorylation associated with EGF-stimulated cells. Preclinical data provide the proof-of-evidence for
a therapeutic targeting of Neu1with Tamiﬂu in impeding humanpancreatic cancer growth andmetastatic spread
in heterotopic xenografts of eGFP-MiaPaCa-2 tumors growing in RAGxCγ double mutant mice. Tamiﬂu-treated
cohort exhibited a reduction of phosphorylation of EGFR-Tyr1173, Stat1-Tyr701, Akt-Thr308, PDGFRα-Tyr754
and NFκBp65-Ser311 but an increase in phospho-Smad2-Ser465/467 and -VEGFR2-Tyr1175 in the tumor lysates
from the xenografts of human eGFP-MiaPaCa-2 tumor-bearing mice. The ﬁndings identify a novel promising
alternate therapeutic treatment of human pancreatic cancer.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license. atrix metalloproteinase; RTKs,
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Molecular-targeting therapeutics directed towards growth factor
receptors have become promising interventions in cancer. These
growth factor receptors are over-expressed during the progression of
pancreatic cancer [1]. They include the family of mammalian receptor
tyrosine kinases (RTKs) such as epidermal growth factor (EGF),
platelet-derived growth factor (PDGF), ﬁbroblast growth factor (FGF),
vascular endothelial growth factor (VEGF), nerve growth factor (NGF)
and insulin. In particular, the EGF receptor is one of the most well-
knownmembers of the RTK family of receptors. It exists as single, highly
glycosylated subunits on the cell surface membrane.When EGF binds to
the extracellular ligand-binding domain of EGFR, the receptor undergoes
a conformational change and dimerizes with adjacent EGFRs. This pro-
cess results in the activation of the receptor's intracellular tyrosine kinase
domains, and consequently, the autophosphorylation of speciﬁc intracel-
lular tyrosine residues. Reports from protein crystallography studies
[2,3], sequence analyses of ligand binding to extracellular domains of
EGFR [4–7], and receptor dimerization analyses [8] strongly conclude
that the EGFR dimerization is an essential required step in the receptor
activation mechanism. Although the ligand-binding and the receptor di-
merization steps are both critical for EGFR activation, the molecular
mechanism(s) behind these two events still remains unknown [9].se. 
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may in fact be the invisible link connecting ligand-binding and receptor
dimerization [10–13].
This present report describes another molecular level of a novel
organizational signaling platform linked to the EGF-induced recep-
tor activation process in live EGFR-expressing cells. Here, EGF
binding to its receptor induces an endogenous Neu1 and matrix
metalloproteinase-9 (MMP-9) cross-talk in activating EGFRs. Central
to this process is that Neu1 and MMP-9 form a complex tethered at
the ectodomain of EGFRs on the cell surface. This signaling paradigm
proposes that EGF binding to its receptor on the cell surface induces a
conformational change of the receptor to initiate MMP-9 activation to
induce Neu1. Activated Neu1 hydrolyzes α-2,3-sialyl residues linked
to β-galactosides, which are distant from the EGF binding sites. These
ﬁndings predict a prerequisite desialylation process by activated Neu1
enabling the removal of steric hindrance to receptor association which
is stabilized by galectin-3. This Neu1–MMP-9 crosstalk in alliance with
EGF receptors at the ectodomain forms the essential signaling platform
on the cell surface that is critical for EGF-induced receptor activation.
Preclinical molecular-targeting studies focused on inhibiting Neu1 as
the key central enzyme within this novel EGFR signaling paradigm pro-
vide the proof-of-evidence for an effective Tamiﬂu monotherapy in the
treatment of human pancreatic cancer growth and metastatic spread in
heterotopic xenograft of tumors growing in RAG2−/−xCγ−/− doublemu-
tant mice. Taken together, these ﬁndings identify for the ﬁrst time that
Neu1 may be an important cancer-targeting enzyme which is proposed
to be unaffected by the activating mutations in cancer cells.
2. Materials and methods
2.1. Cell lines
The NIH3T3–hEGFR cell line is a mouse ﬁbroblast cell line which
overexpresses human EGFRs [14,15] (kindly provided by Dr. L. Raptis,
Queen's University, Kingston, Ontario, Canada). The wild-type NIH3T3
mouse ﬁbroblast cell line which expresses low to undetectable levels of
EGFR was used as a negative control. The A431 (ATCC® CRL-2592™)
cells are a human skin epidermoid carcinoma cell line. The cell lines
were grown in 1× Dulbecco's Modiﬁed Eagle Medium (DMEM, Gibco,
Rockville, MD) containing 10% fetal calf serum (FCS) (HyClone, Logan,
Utah, USA), and were maintained at 5% CO2 and 37 °C.
WG0544 and 1140F01 sialidosis ﬁbroblast cell lines are Neu1
deﬁcient skin ﬁbroblast cells that were isolated from patients with lyso-
somal storage disorder type 1 sialidosis and immortalized [16]. These
cells were kindly provided by Dr. Alexey Pshezhetsky, Department of
Pediatrics and Biochemistry, Montreal University, Service de Genetique,
Ste-Justine Hospital, 3175 Cote-Ste-Catherine, H3T1C5, Montreal, QC,
Canada. Cells were grown in 1× DMEMmedium containing 10% FCS.
The PANC-1 (ATCC® CRL-1469™) cells are a human pancreatic
ductal epithelial carcinoma cell line which overexpresses EGFRs on its
surface. Mia-PaCa-2 cells (ATCC® Number: CRL-1420™) are human
pancreatic cancer cell line with attached epithelial and with ﬂoating
rounded cells expressing the 17 beta-estradiol (E2)-binding estrogen
receptor and derived from a male patient with carcinoma. All cells
were grown at 37 °C in 5% CO2 in culture media containing Dulbecco's
Modiﬁed Eagle Medium (DMEM) (Gibco, Rockville, MD) supplemented
with 10% fetal calf serum (FCS) (HyClone, Logan, Utah, USA).
2.2. eGFP Lentifect puriﬁed lentivirus particles
GeneCopoeia Lentifect™ lentiviral particles (Cat# LP-EGFP. LV105-
0205) are ready-to-use particles. They are produced from a standard-
ized protocol using puriﬁed plasmid DNA and the proprietary reagents,
EndoFectin™ Lenti (for transfection) and TiterBoost™ solution. The
protocol uses a third generation self-inactivating packaging system
meeting BioSafety Level 2 requirements with the University Biohazardcommittee approval. The Lentifect particles include a CMV promoter
for efﬁcient expression of non-tagged eGFP in target cells and use a
puromycin resistance marker for selection of stably transduced cells.
Ready-to-use lentiviral particles were used for the transduction of
MiaPaCa-2 and PANC-1 cells.
Brieﬂy, cells were cultured in 6 well tissue culture plates in DMEM
medium containing 10% FCS and 5 μg/mL plasmocin. After 24 h, medi-
um was discarded and 2 mL of 5 μg/mL of polybrene media was added
to the cells followed by eGFP lentiviral particles at MOI = 6. The plate
was mixed, centrifuged at 2500 rpm for 90 min. and incubated at
37 °C in 5% CO2 humidiﬁed incubator for 24 h. The cells were washed
and re-cultured in media for additional 2 days. On day 5, the media
were replacedwith selectionmedia containingoptimal 2 μg/mL of puro-
mycin as pre-determined in a cell viability assay. Selection media was
added every 40 h to expand puromycin-resistance eGFP transduced
MiaPaCa-2 cell clones. The transfection efﬁciency of 90%was determined
using ﬂuorescencemicroscopy (Zeiss ImagerM2) and biophotonic imag-
ing (Cancer Biology & Genetics Division of the Queen's Cancer Research
Institute) before implantation into the mice.
2.3. Reagents
Epidermal growth factor (EGF; Sigma-Aldrich, St. Louis, MO), the
natural ligand of the EGFR, was reconstituted in sterile 1× phosphate
buffered saline (PBS) at a stock concentration of 1 mg/mL and stored
at −20 °C. EGF concentration to stimulate cells was 30–100 ng/mL.
Incubation times vary between experiments and thus are indicated.
Maackia amurensis lectin 2 (MAL-2) (Vector Laboratories Inc., Burling-
ton, Ontario, Canada) binds speciﬁcally to α-2,3 sialic acid linked to
terminal β-galactose. Sambucus nigra lectin (SNA which binds to α-2,6
sialic acid linked to terminal β-galactose and to lesser degree α-2,3
linkage), peanut agglutinin (PNA, galactosyl (β-1,3) N-acetylgalactosa
mine), and succinylated wheat germ agglutinin (sWGA, N-acetylgluco
samine residues) were used in these studies.
2.4. Inhibitors
Tamiﬂu (La Roche Ltd., Mississauga, Ontario) was used at indicated
concentrations. MMP-3 inhibitor (MMP-3i, Stromelysin-1 Inhibitor,
Calbiochem-EMD Chemicals Inc.) inhibits MMP-3 (IC50 = 5 nM).
MMP-9 inhibitor (MMP-9i, Calbiochem-EMD Chemicals Inc.) is a cell-
permeable, potent, selective, and reversible inhibitor (IC50 = 5 nM). It
also inhibits MMP-1 (IC50 = 1.05 μM) and MMP-13 (IC50 = 113 nM)
only at much higher concentrations. Galardin (GM6001; Calbiochem-
EMD Chemicals Inc., Darmstadt, Germany) is a potent, cell-permeable,
broad-spectrum hydroxamic acid inhibitor of matrix metalloproteinases
(MMPs) (IC50 = 400 pM for MMP1; IC50 = 500 pM for MMP2; IC50 =
27 nM for MMP3; IC50 = 100 pM for MMP8; and IC50 = 200 pM for
MMP9). BIM-46174 is a G-protein inhibitor kindly provided by IPSEN
Innovation (91940 Les Ulis, France). BIM-23127 is a speciﬁc neuromedin
B receptor inhibitor from Tocris Bioscience (Tocris House, IO Centre
Moorend Farm Avenue, Bristol, BS11 0QL, United Kingdom).
2.5. Primary antibodies
Neutralizing antibodies were used to inhibit sialidase function:
rabbit anti-human Neu1 IgG antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), mouse anti-human Neu2 IgG antibody (Santa
Cruz), mouse anti-human Neu3 IgG antibody (Medical & Biological
Laboratories Co., Ltd., Japan), and rabbit anti-human Neu4 IgG antibody
(Proteintech Group, Inc., Chicago, IL 60612, USA). Phosphorylation of
EGFR, Stat1 and NKκBp65 was measured with rabbit anti-EGFR-
Tyr1173, rabbit anti-NFκBp65-Ser(P)311 or rabbit anti-Stat1 p84/
p91(M22) antibodies (Santa Cruz Biotechnology). Mouse anti-galectin-
3, goat anti-MMP-9 IgG antibody and rabbit anti-human EGFR IgG
antibody were all acquired from Santa Cruz Biotechnology. AlexaFluor-
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AlexaFluor 488 (Molecular Probes, Eugene, OR, USA), F(ab′)2 goat
anti-rabbit AlexaFluor 594 (Molecular Probes), and goat anti-mouse
AlexaFluor 594 (Invitrogen, Corp.) were used at predetermined optimal
concentrations. Horse radish peroxidase-labeled goat anti-rabbit anti-
body and donkey anti-goat-HRP antibody were obtained from Santa
Cruz Biotechnology. Streptavidin–HRP was obtained from Cedarlane
Canada, Burlington, Ontario, L7L 5R2.
2.6. Bio-Plex Pro cell phosphoprotein signaling
The procedure uses magnetic bead-based immunoassays for the
detection of intracellular phosphoproteins in cells and tissue lysates.
Bio-Plex Pro phosphoprotein assays measure the relative amount of
the phosphorylated protein only compared to optimized positive and
phosphatase treated negative control samples. Using the multiplex
format, the proﬁles of multiple phosphorylated proteins involved in
cell signaling pathways were detected using only 50 μL of lysate. The
assay is based on 6.5 μm magnetic beads. Assay protocol is optimized
for high sensitivity and higher speciﬁcity in minimizing cross-reactivity
and broad dynamic range using highly speciﬁc antibodies (Akt-Thr-
308, PDGFRα-Tyr754, STAT1-Tyr701, Smad2-Ser465/467 and VEGFR2-
Tyr1175) developed and validated by Cell Signaling Technology, Inc.
Live necropsied tumor tissue taken from untreated and Tamiﬂu treated
cohorts were immediately weighted and snap-frozen on dry ice. Using
lysing buffer containing cocktail of proteinase and phosphatase inhibi-
tors, freshly frozen tumor tissues were dounce homogenized on ice to
obtain individual tumor lysates from each tumor-bearing mouse. Total
protein concentration was determined by Bradford Assay reagent
and adjusted equally for Bio-Plex Pro analyses using the Bio-Plex
200 System.
2.7. Sialidase assay in live cells
Cells were grown overnight on 12 mm circular glass slides in condi-
tioned medium in a sterile 24-well tissue plate until they reached ~70%
conﬂuence as previously optimized in the live cell sialidase assay
[17,18]. After removing medium, 0.318 mM 4-MUNANA (2′-(4-
methylumbelliferyl)-α-D-N-acetylneuraminic acid; Biosynth Intl.) sub-
strate in Tris-buffered saline (TBS) pH 7.4 was added to each well
alone (control), with predetermined dose of EGF (30 ng/mL), or in
combination of EGF and inhibitor or neutralizing antibodies at the indi-
cated concentrations. The substrate is hydrolyzed by sialidase to give
free 4-methylumbelliferone which has a ﬂuorescence emission at
450 nm (blue color) following an excitation at 365 nm. Fluorescent
images were taken after 1–2 min using epi-ﬂuorescent microscopy
(40× objective). The mean ﬂuorescence surrounding the cells was
quantiﬁed using the Image J program.
2.8. Immunocytochemistry of EGFR phosphorylation
3T3–hEGFR or A431 cells were grown overnight on 12 mm circular
glass slides in a 24-well tissue culture plate at 37 °C until cells reached
~70% conﬂuence. NIH3T3–hEGFR cells were pretreated with 200 μM
Tamiﬂu or 100 μg/mL neutralizing anti-Neu antibodies (Neu1, -2, -3,
or -4) for 30 min followed by 30 ng/mL EGF for 5 min, or left untreated
as controls (media). A431 cells were pretreatedwith lectins at indicated
doses for 30 min followed by 100 ng/mL EGF for 5 min or left untreated
as controls. Cells were ﬁxed, permeabilized, and immunostained with
rabbit anti-human pEGFR for 60 min followed by speciﬁc AlexaFluor
secondary antibodies for 60 min at 37 °C. Stained cells were visualized
by epi-ﬂuorescence microscopy using a 40× objective. Quantitative
analysis was done by assessing the density of cell staining corrected
for background in each panel using Corel Photo Paint 8.0 software.
Each bar in the ﬁgures represents the mean corrected density of stain-
ing ± S.E. for all cells (n) within the respective images.For the immunocytochemistry of galectin-3, cells were cultured on
12 mm circular poly-D-lysine-treated coverslips in 24-well cell culture
plates (Corning Inc., New York, USA) for 24 h in a humidiﬁed incubator
at 37 °C and 5% CO2. After the media were removed, certain cells were
treated with inhibitors, 56.6 μg/mL Tamiﬂu or 200 μg/mL rabbit anti-
human Neu1, for 30 min, and subsequently stimulated with 50 ng/mL
EGF for 5 min. Other cells were treated purely with 50 ng/mL EGF,
56.6 μg/mL Tamiﬂu, or 200 μg/mL rabbit anti-human Neu1. The control
cells were neither inhibited nor stimulated. All cells were then ﬁxed
with 4% paraformaldehyde and permeabilized with 0.2% Triton X-100.
Next, cells were treated with 4% bovine serum albumin (BSA) in
Tween–Tris buffered saline (TTBS) to prevent non-speciﬁc binding in
subsequent immunostaining with primary antibody and secondary
antibody over 1-hour periods. The primary antibody contained 2 μg/mL
mouse anti-galectin-3 whereas the secondary antibody held 40 μg/mL
goat anti-mouse IgG AlexaFluor 594. The stained cells were observed by
confocal microscopy (Leica TCS SP2 MP inverted confocal microscope)
at 100× magniﬁcation (oil), and the results were analyzed with Image J
and GraphPad Prism software.
2.9. Co-localization
For co-localization between galectin-3 and EGFR, cells were cultured
on 12 mm circular poly-D-lysine-treated coverslips in 24-well cell
culture plates (Corning Inc., New York, USA) for 24 h in a humidiﬁed
incubator at 37 °C and 5% CO2 prior to stimulation with 500 ng/mL
EGF for 5 min. Cells were then ﬁxed with 4% paraformaldehyde and
treated with 4% BSA in TTBS (Tris buffered saline containing 0.2%
Tween-20) to prevent non-speciﬁc binding in subsequent immuno-
staining with primary antibodies and secondary antibodies over 1-
hour periods. While the primary antibodies included 4 μg/mL mouse
anti-galectin-3 and 4 μg/mL rabbit anti-EGFR, the secondary antibodies
contained 40 μg/mL goat anti-mouse IgG AlexaFluor 594 and 40 μg/mL
goat anti-rabbit IgG AlexaFluor 488. The stained cells were viewed by
ﬂuorescence microscopy using 100× objective (oil). To quantitatively
measure co-localization, the Pearson correlation coefﬁcient was com-
puted and expressed as a percentage using Image J software.
2.10. Western blot for pEGFR
3T3–hEGFR cells were grown at 37 °C in 5% CO2 in culture media
until they reached ~80% conﬂuence. The cells were treated with either
250 μg/mL Tamiﬂu or anti-Neu1 antibodies for 1 h followed by stimula-
tionwith30 ng/mL EGF for 30 min or left untreated as controls (media).
They were immediately lysed in 500 mL of 1× SDS sample buffer
containing 1 μL protease inhibitor cocktail on ice for 30 min. To each
cell lysate was added 1% 2-mercaptoethanol and boiled for 10 min.
Cells were pelleted at 13,000 rpm for 10 min at 4 °C. The supernatant
was retained and stored at −80 °C. For each sample, 60 μg protein,
10 μL Loading Buffer (Sample Buffer + 5% β-mercaptoethanol), and
up to 10 μL lysis buffer were added to make a ﬁnal volume of 20 μL
per tube. Samples were boiled at 80 °C for 10 min and loaded into an
8% SDS-PAGE gel. The gel was run for 2 h at 100 V. Proteins were then
transferred onto PVDF via semi-dry blotting for 80 min at 100 mA.
The blot was blocked in 2% BSA in 0.1% Tween–TBS for 60 min at
20 °C, followed by rabbit anti-human pEGFR antibody (Santa Cruz)
overnight at 4 °C. The following day, the blot was probed with
8 μg/mL HRP-conjugated secondary goat anti-rabbit for 75 min at
20 °C and Western Lightning Chemiluminescence Reagent Plus. NIH3T3
cells served as a negative control in this experiment. After development,
blots were stripped and reprobed with rabbit anti-human panEGFR
(Santa Cruz) as a loading control. β-Actin was also used as an internal
control protein for loading of the cell lysate. Sample concentration for
gel loadingwas determined by Bradford Assay reagent. Quantitative anal-
ysiswas done by assessing the density of a band corrected for background
in each lane using Corel Photo Paint 8.0 software.
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3T3–hEGFR or NIH3T3 cells were treated with 30 ng/mL of EGF, in
combination with indicated inhibitors and EGF or left untreated in
media as controls for the indicated time intervals. Cells (1 × 107 cells)
were pelleted and lysed in lysis buffer (50 mM Tris, pH 8, 150 mM
NaCl, 1% NP-40, 0.2 mg/mL leupeptin, 1% β-mercaptoethanol, and
1 mM phenyl-methanesulfonyl ﬂuoride (PMSF). For immunoprecipita-
tion, EGFR, TLR4 and MMP-9 in cell lysates from BMA cells were
immunoprecipitated with 1.0 μg of goat anti-EGFR, 1 μg of mouse
anti-Neu2, 1 μg of mouse anti-Neu3 or 1 μg rabbit anti-Neu4 antibodies
for 24 h at 4 °C. Following immunoprecipitation, complexes were
isolated using protein A or G magnetic beads, washed 3× in buffer
(10 mM Tris, pH8, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 1% Triton
X-100 and 0.2 mM sodium orthovanadate) and resolved by 8% gel elec-
trophoresis (SDS-PAGE). Proteins were transferred to polyvinylidene
ﬂuoride (PVDF) transfer membrane blot. The blots were probed for
either Neu1 with anti-Neu1 (Santa Cruz Biotechnology, Inc. CA),
EGFR with anti-EGFR or MMP-9 (88 kDa) with anti-MMP-9 (H-129,
Santa Cruz Biotech) followed by HRP conjugated secondary IgG anti-
bodies or Clean-Blot IP Detection Reagent for IP/Western blots
(Pierce Biotechnology, Thermo Fisher Scientiﬁc, Rockford, IL) and
Western Lightning Chemiluminescence Reagent Plus. The chemilu-
minescence reaction was analyzed with X-ray ﬁlm. Sample concen-
tration for gel loading was determined by the Bradford reagent
(Sigma-Aldrich). NIH3T3 cells, as well as NIH3T3–hEGFR cells
which were not incubated with anti-hEGFR antibody prior to the
immunoprecipitation step, served as negative controls in these
experiments. In the co-immunoprecipitation experiments of EGFR
with Neu2, -3, or 4, a Western blot of untreated NIH3T3–hEGFR
cells was run simultaneously in order to determine if the NIH3T3–
hEGFR cells expressed detectable levels of Neu-2, -3, and -4 protein.2.12. Cell surface biotinylation and Western blot of immunoprecipitated
biotinylated proteins
3T3–hEGFR cells were grown in 75 cm2 ﬂasks until they reached
~80% conﬂuence. Cells were left untreated (control), stimulated with
30 ng/mL EGF for 5 min, or inhibited with 400 μM Tamiﬂu, 100 μg/mL
anti-Neu1 neutralizing antibody, or 50 μg/mL MMP-9 inhibitor for
30 min prior to 30 ng/mL EGF stimulation for 5 min. Cells were washed
three times in cold 1× PBS. Cell concentration for each sample was
adjusted to 5 × 106 cells/mL. A biotin solution was prepared which
consisted of 1 mg NHS-SS-Biotin (Pierce), 14 μL dimethyl sulfoxide
(DMSO; Bio-Rad), and 151 μL 1× PBS. 80 μL of the prepared biotin
solution was added to 1 mL of cell suspension and incubated on ice
for 30 min. Cells were washed 4 times in 1× PBS. Each cell sample
was resuspended in 99 μL of prepared lysis buffer (50 mM Tris,
150 mM NaCl, 1 mM PMSF, 1% NP-40, 0.2 mg/mL leupeptin, 1% β-
mercaptoethanol) and 1 μL of protease inhibitor cocktail, and then
allowed to incubate on ice for 30 min. Cells were spun down at
13,000 rpm for 10 min. The supernatant was retained and protein
concentration was determined via the Bradford Assay.
Cell lysates (100 μL) were immunoprecipitated with 1 μg of goat
anti-EGFR antibody (Santa Cruz) overnight at 4 °C. Samples were incu-
batedwith 10 μL of ProteinGmagnetic beads (NewEngland Biolabs) for
90 min at 4 °C. Samples were washed with the assistance of a magnetic
rack, loaded into an 8% SDS-PAGE gel, and run at 100 V for 2 h. The pro-
teins were transferred onto PVDF via semi-dry blotting for 80 min at
100 mA. The blot was blocked in 2% BSA in 0.1% Tween–TBS overnight
at 4 °C, followed by incubation with streptavidin–HRP (Cedarlane) for
90 min at room temperature. The blot was treated with Western
Lightning Chemiluminescence Reagent Plus for 5 min. The chemilumi-
nescence reaction was analyzed with X-ray ﬁlm. NIH3T3 cells as well
as unstimulated 3T3–hEGFR cells which were not incubated with goatanti-EGFR antibody prior to the immunoprecipitation step served as
negative controls in this experiment.
2.13. Heterotopic xenograft mouse model of human pancreatic cancer
An immunodeﬁcient mouse model with a double mutation in the
combining recombinase activating gene-2 (RAG2) and common cytokine
receptor γ chain (Cγ) was used as xenograft mice. The RAG2−/−xCγ−/−
double mutant mice on a BALB/c genetic background are completely
alymphoid (T-cell, B-cell, and NK-cell deﬁcient), show no spontaneous
tumor formation, and exhibit normal hematopoietic parameters. Mice
were generated by inter-crossing and were maintained in SPF isolators
in the Animal Care Facility, Queen's University, Kingston, Ontario
K7L3N6, Canada. A colony was established in the animal facility. All
mice were kept under sterile conditions in micro-isolators or air-ﬁltered
cages, and were provided with autoclaved food and water. All mice
used in the studies were approved by the Animal Care Committee,
Queen's University. They were used between 6 and 8 weeks of age.
2.14. Cancer cell implantation in RAG-2−/−xCγ−/− double mutant xeno-
graft mice
Puromycin-resistance eGFP transduced MiaPaCa-2 cell clones were
grown in 75 cm2 cell culture ﬂask at 80% conﬂuence. The cells were
resuspended into solution using TrypLE Express (Gibco) and washed
with sterile saline. The cell suspension was centrifuged for 3 min at
900 rpm, and the cell pellet suspended in sterile saline at a concentra-
tion of 5–10 × 106 cells/mL for 1 × 106 cell implantation cutaneously
into the right back ﬂank of the mouse. Tumor measurements were
taken twice a week. Tumor volumes were determined by (width
square / 2) × length. At the endpoint of the experiment, mice were
euthanized by cervical dislocation and live necropsy tumor, liver, lung,
and heart were biophotonic imaged for ﬂuorescence of eGFP-
MiaPaCa-2 cells, tumor weights, and hematoxylin and eosin (H&E)
staining of parafﬁn embedded tissues.
2.15. Statistical analysis
Statistical analysis was carried out using GraphPad Prism 5. Results
were compared by a one-way ANOVA at 95% conﬁdence using
Bonferroni's multiple comparison test.
3. Results
3.1. Neu1 sialidase activity is associated with epidermal growth factor
(EGF) stimulation of EGFR-expressing cells
Our previous report demonstrated that nerve growth factor (NGF)
binding to TrkApotentiatesG-protein coupled receptor (GPCR)-signaling
via membrane Gαi subunit proteins and matrix metalloproteinase-9
(MMP-9) activation to induce Neu1 in live primary neurons and TrkA-
and TrkB-expressing cell lines [19]. A similar Neu1–MMP-9 cross-talk
was identiﬁed by us for TOLL-like receptors [20]. Since EGF receptors
belong to the same family of tyrosine kinase receptors like TrkA, we
initially asked whether there was a similar mammalian cellular sialidase
associated with EGFRs. Using a mouse embryonic 3T3 ﬁbroblast cell line
expressing human EGFR (3T3–hEGFR), we performed a sialidase assay
on the live cells as previously described [18,21,22]. As shown in Fig. 1A,
EGF stimulation of live 3T3–hEGFR cells dose-dependently induced
sialidase activity. This sialidase activity is revealed in the periphery
surrounding the cells using a ﬂuorogenic sialidase speciﬁc substrate, 4-
MUNANA [2'-(4-methylyumbelliferyl)-α-D-N-acetylneuraminic acid],
which ﬂuoresces at 450 nm and caused by the emission of 4-
methylumbelliferone. The mean ﬂuorescence of 50 multi-point repli-
cates was quantiﬁed using the Image J software and is depicted in the
bar graph. We also used speciﬁc neutralizing antibodies against the
Fig. 1. (A) EGF induces sialidase activity in live NIH3T3–hEGFR cells in a dose-dependent manner. 3T3–hEGFR cells were allowed to adhere on 12 mm circular glass slides in media con-
taining 10% fetal calf sera for 24 h. After removingmedia, 0.318 mM 4-MUNANA (4-MU) substrate (2′-(4-methlyumbelliferyl)-α-N-acetylneuraminic acid) in Tris buffered saline pH 7.4
was added to live cells alone (control) or with EGF at the indicated doses. The substrate is hydrolyzed by sialidase enzymes to give free 4-methylumbelliferone, which has a ﬂuorescence
emission at 450 nm (blue color) following excitation at 365 nm. Fluorescent images were taken at 2 min after adding substrate using epi-ﬂuorescent microscopy (10× objective). The
mean ﬂuorescence of 50multi-point replicates was quantiﬁed using the Image J software. The data are a representation of one out of three independent experiments showing similar re-
sults. (B) EGF-induced sialidase activity in live NIH3T3–hEGFR cells is blocked by anti-Neu1 and not with anti-Neu-2, -3, or -4 neutralizing antibodies. EGF-induced sialidase activity in live
NIH3T3–hEGFR cells wasmeasured as described in (A). Cells were treated with 30 ng/mL EGF alone, in combination with 200 μM Tamiﬂu, in combination with 100 μg/mL of either anti-
Neu-1, -2, -3, or -4 neutralizing antibodies or left untreated as control cells. The mean ﬂuorescence of 50 multi-point replicates was quantiﬁed using the Image J software. The data are a
representation of one out of four independent experiments showing similar results. (C) EGF induces sialidase activity in livewild-type humanﬁbroblast cells but not inWG544 or 1140F01
Neu1-deﬁcientﬁbroblast cells derived from type 1 sialidosis patients. EGF-induced sialidase activity in live humanﬁbroblast cellswasmeasured as described in (A). Cellswere treatedwith
30 ng/mL EGF or left untreated as control cells. The data are a representation of one out of four independent experiments showing similar results. (C) Tamiﬂu inhibits EGF-induced
sialidase activity in 3T3–hEGFR cells in a dose dependent manner. EGF-induced sialidase activity in live cells was measured as described in (A). Fluorescent images were taken at
2 min after adding 0.318 mM 4-MU substrate together with EGF and indicated concentrations of Tamiﬂu using epi-ﬂuorescent microscopy (10× objective). The mean ﬂuorescence
surrounding the cells for each of the images was measured using Image J Software. The data are a representation of one out of three independent experiments showing similar results.
(D) The 50% inhibition concentration (IC50) for Tamiﬂu on sialidase activity induced by EGF in live 3T3–hEGFR cells. The 50% inhibitory concentration (IC50) of Tamiﬂu was determined
by plotting the decrease in sialidase activity against the log of the inhibitor concentration.
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cytosolic Neu2, the plasma membrane bound Neu3 [31–33] and the
fourth sialidase, Neu4, localized to either the mitochondrial [34]
compartment or the lysosomal lumen [35]. As shown in Fig. 1B, anti-
human Neu1 antibody as well as the neuraminidase inhibitor Tamiﬂu
blocked the sialidase activity associated with EGF-treated live 3T3–
hEGFR cells comparable to the levels of no EGF treated controls. The
anti-Neu1 antibody used here is speciﬁc for the epitope corresponding
to amino acids 116–415 mapping at the C-terminus of Neu1 of human
origin. It also detects Neu1 of mouse, rat and human origin. In contrast,
antibodies against the other three human sialidases, Neu-2, -3 and -4
had no blocking effect on sialidase activity associated with EGF stimulat-
ed live 3T3–hEGFR cells similar to the mean ﬂuorescence levels of EGF
positive control (Fig. 1B). These latter results using neutralizing antibod-
ies are consistent with our previous report with TOLL-like receptors [22].
It was not surprising that this EGF-induced sialidase activity wascompletely blocked by the neuraminidase inhibitor Tamiﬂu (pure
oseltamivir phosphate) at 200 μM as shown in Fig. 1B but also in a
dose dependent range of 0.25–250 μg/mL (Fig. 2C). To further elucidate
the inhibitory capacity of Tamiﬂu, the 50% inhibitory concentration
(IC50) of the compound was determined by plotting the decrease in
sialidase activity against the log of the agent concentration. As shown
in Fig. 2D, Tamiﬂu had an IC50 of 4.86 μM which is comparable to the
reported IC50 of 3.876 μM for NGF-TrkA [19] and 1.175 μM for LPS-TLR-
4 [22] ligand-induced sialidase activity in TrkA-PC12 and BMC-2
macrophage cells, respectively. For NGF-induced sialidase activity in
TrkA-expressing cells, we also reported that other puriﬁed neuramini-
dase inhibitors such as zanamivir (4-guanidino-Neu5Ac2en) and
oseltamivir carboxylate had a limited inhibition of NGF-induced
sialidase activity in live TrkA-PC12 cells at 1–2 mM compared to the
NGF positive control [19]. Other studies using recombinant soluble
human sialidases have shown that oseltamivir carboxylate, the active
Fig. 2. (A) Tamiﬂu and anti-Neu1 neutralizing antibody inhibit EGF induced EGFR phosphorylation (pEGFR) in 3T3–hEGFR cells. Cellswere grown overnight on glass coverslips in a 24-well
tissue culture plate at 37 °C for 24 h or until they reached ~70% conﬂuence. Cells were stimulated with 30 ng/mL EGF for 5 min, pretreated with 200 μM Tamiﬂu for 30 min followed by
30 ng/mL EGF for 5 min, or pretreatedwith 100 μg/mL anti-Neu1, -2, -3, or -4 neutralizing antibodies for 30 min followed by 30 ng/mLEGF for 5 min. Cellswere left untreated as no ligand
controls. Cells were ﬁxedwith 4% paraformaldehyde, permeabilizedwith Triton X, and blockedwith 4% bovine serum albumin (BSA) in 0.1% Tween–Tris buffered saline (TBS) for 20 min
on ice. Cells were immunostained with rabbit anti-human pEGFR for 60 min at 37 °C, followed by AlexaFluor 594 goat anti-rabbit secondary antibody for 60 min at 37 °C. Control group
had only secondary antibodieswith noother treatment. Stained cellswere visualized by epi-ﬂuorescencemicroscopywith a 40× objective. Quantitative analysiswas doneby assessing the
density of cell staining corrected for background in each panel using Corel Photo Paint 8.0 software. Each bar in the ﬁgure represents themean corrected density of culture cell staining ±
SEM for equal cell density (5 × 105 cells) within the respective images. The data are a representation of one out of three independent experiments showing similar results. (B) Western
blot analyses of Tamiﬂu and anti-Neu1 neutralizing antibody inhibition of EGF-induced pEGFR in 3T3–hEGFR cell lysates. Cell were treated 30 ng/mL EGF for 5 min or pretreated with
either 400 μM Tamiﬂu or 100 μg/mL anti-Neu1 neutralizing antibody for 30 min or left untreated as control (media). Cells were pelleted, lysed in lysis buffer and the cell lysates were
resolved by SDS-PAGE. The blot was probed with 0.14 μg/mL rabbit anti-human pEGFR antibody overnight at 4 °C followed by 40 ng/mL horse radish peroxidase-labeled goat anti-
rabbit antibody for 75 min at 20 °C and Western Lightning Chemiluminescence Reagent Plus for 5 min. NIH3T3 cells served as EGFR negative control. After development, blots were
stripped and re-probed with rabbit anti-human pan-EGFR as a loading control. The data are a representation of one out of three independent experiments showing similar results.
(C) A Western blot was performed as described in (B) above, but 3T3–hEGFR cells were stimulated with 30 ng/mL EGF for 10 min. (D) Immunoprecipitation of EGFR and Western blot
analyses of biotinylated cell surface of 3T3–hEGFR cells in the presence of Tamiﬂu, anti-Neu1 neutralizing antibody and speciﬁc MMP-9 inhibitor. Cells were left untreated (control),
stimulated with 30 ng/mL EGF for 5 min, or pretreated with 400 μM Tamiﬂu, 100 μg/mL anti-Neu1 neutralizing antibody or 50 μg/mL MMP-9 inhibitor for 30 min followed by 30 ng/mL
EGF stimulation for 5 min. Cells were biotinylated with NHS-SS-biotin on ice for 30 min, extensively washed, pelleted and lysed in lysis buffer. The EGFR in the cell lysates was
immunoprecipitated with 1 μg of goat anti-EGFR antibody overnight at 4 °C. Immunocomplexes were isolated using protein G magnetic beads, resolved by SDS-PAGE and the blot probed
with streptavidin–HRP followedbyWestern LightningChemiluminescenceReagent Plus. NIH3T3 and3T3–hEGFR cells thatwerenot immunoprecipitated (no IPAb) served asnegative controls.
The data are a representation of one out of two independent experiments showing similar results. (E)Maackia amurensis lectin 2 (MAL-2) dose-dependently inhibits EGF-induced pEGFR in
human skin epidermoid carcinoma A431 cell line. A431 cells were starved in serum freemedia for 24 h. The cells were pretreated with MAL-2, Sambucus nigra lectin (SNA), peanut agglutinin
(PNA) and succinylated wheat germ agglutinin (sWGA) lectins at indicated doses for 30 min followed by 30 ng/mL EGF for 5 min or left unstimulated as control. Cells were ﬁxed with 4%
paraformaldehyde, permeabilized with Triton X100 and immunostained with mouse anti-pEGFR followed by AlexaFluor 488 rabbit anti-mouse IgG. Stained cells were visualized by epi-
ﬂuorescence microscopy using a 40× objective. Quantitative analysis was done by assessing the density of cell staining corrected for background in each panel using Corel Photo Paint 8.0
software. Each bar in the graphs represents the mean corrected density of staining ± S.E. (error bars, n = 4) for equal cell density (5 × 105 cells) within the respective images. Results were
compared by a one-way ANOVA at 95% conﬁdence using Bonferroni's multiple comparison test. The data are a representation of one of ﬁve independent experiments showing similar results.
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sialidases even at 1 mM [36], while zanamivir signiﬁcantly inhibited the
humanNeu2 andNeu3 sialidases in themicromolar range. Other studies
have found that zanamivir and DANA (2-deoxy-2,3-didehydro-N-
acetylneuraminic acid) inhibit endogenous sialidase activity of activated
lymphocytes grown in culture, as evidenced by an altered sialylation
pattern of cell surface proteins, and that this inhibition of sialidaseactivity resulted in a reduced production of IFN-γ mRNA and protein
in the 1–2 mM range [26].
To conﬁrmNeu1 sialidase activity associatedwith EGF stimulated live
cells at the genetic level, we used human 1140F01 and WG0544 type 1
sialidosis ﬁbroblast cell lines with the live cell sialidase assay. Patients
with type 1 sialidosis or mucolipidosis-1 have a Neu1 genetic deﬁciency
which is a human autosomal recessive inborn error of metabolic disease.
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tissues and urine causing neuropathic or non-neuropathic symptoms
depending on the onset of the disease. The data in Fig. 1E clearly indicate
a lack of sialidase activity associated with EGF stimulation of these live
Neu1-deﬁcient cells compared to the wild-type cells. These latter data
provide additional supporting evidence for Neu1 involvement with EGF
activation of live EGFR expressing cells. It is noteworthy that the ﬂuores-
cence associated with ligand treated cells as seen in Fig. 1 is not due to a
form of secreted or shed sialidase from the cells as described previously
[21,22]. The live cells treated with the substrate alone do not show ﬂuo-
rescence surrounding the cells, consistent with our other reports [19,22].
Taken together, these results suggest that the diffuse ﬂuorescence associ-
ated with EGF treated live cells is due to an activation of Neu1 on the cell
surface.
3.2. EGF-induced phosphorylation of EGFR is dependent on Neu1 sialidase
activity
If EGF-induced receptor phosphorylation is dependent on Neu1
activity, then neuraminidase inhibitor like Tamiﬂu or anti-Neu1
neutralizing antibody should have an inhibitory effect on EGF-induced
phosphorylation of EGFR (pEGFR) in 3T3–hEGFR cells. Immunocyto-
chemistry analyses shown in Fig. 2A demonstrate that Tamiﬂu and
anti-Neu1 antibody but not anti-Neu-2, -3 or -4 antibodies markedly
inhibited EGF-induced pEGFR in 3T3–hEGFR cells compared to the EGF
treated controls. Western blot analyses conﬁrmed that Tamiﬂu and
anti-Neu1 antibodies completely inhibited EGF-induced pEGFR in
3T3–hEGFR cells compared to the 5 min (Fig. 2B) and 10 min (Fig. 2C)
EGF treated controls. These results are consistent with our other report
indicating that Tamiﬂu also signiﬁcantly inhibits TLR4 ligand LPS- or
TLR2 ligand zymosan-induced NFκB activation in primary macrophage
cells, LPS-induced pro-inﬂammatory IL-6 and TNFα cytokines, and
LPS-induced nitric oxide production [22].
To conﬁrm that the treatment protocol by Tamiﬂu, anti-Neu1 anti-
body or MMP-9i had no effect on reducing the expression of EGFR on
the cell surface post-EGF stimulation or treatments, we performed a
biotinylation of the cell surface of live 3T3–hEGFR cell post-treatments,
immunoprecipitated EGFR in the cell lysates with speciﬁc antibodies,
and probed the blots with streptavidin–HRP and Western Lightning
Chemiluminescence Reagent Plus. The data shown in Fig. 2D revealed a
predominant cell surface expression of EGFR regardless of the treat-
ments. These observations signify that Tamiﬂu, anti-Neu1 antibodies
and MMP9i had a direct inhibitory effect on the Neu1 activity associated
with EGF treated cells, and not due to an internalization of EGF-
stimulated receptors.
3.3. Identiﬁcation of a speciﬁc sialyl α-2,3-linked to β-galactosyl residues of
EGFR involved in receptor activation
If Neu1 sialidase is involved in the activation of EGFR, it should be
possible to block its activity prior to EGF stimulation. Human epithelial
squamous carcinoma A431 cells were pretreated with different lectins
at various doses (1, 10 and 100 μM) for 30 min, washed and stimulated
with 30 ng/mL of EGF for 5 min. The cells were ﬁxed, permeabilized,
and immunostained with rabbit anti-pTyr1173 residue of EGFR follow-
ed by AlexaFluor 568 anti-rabbit IgG. Stained cells were visualized by
epi-ﬂuorescence microscopy. M. amurensis lectin MAL-2 signiﬁcantly
(p b 0.05) blocked EGF-induced pEGFR dose-dependently (Fig. 2E). In
contrast, S. nigra lectin (SNA, which binds to α-2,6 sialic acid linked to
terminal galactose and to lesser degree α-2,3 linkage), peanut aggluti-
nin (PNA, galactosyl (β-1,3) N-acetylgalactosamine) and succinylated
wheat germ agglutinin (sWGA, N-acetylglucosamine residues) did not
signiﬁcantly block EGF-induced pEGFR activation. These ﬁndings are
consistent with our previous report and that neither MAL-2 nor SNA
treatment of TrkA-expressing cells blocked NGF binding to TrkA [21].
Together, these results suggest that MAL-2 lectin binding to EGFR-expressing cells at α-2,3-sialic acid linked to terminal β-galactoside
residues blocks EGF-induced pEGFR. It is proposed that the activity of
Neu1 tethered to EGFR hydrolyzes these α-2,3-sialyl residues, enabling
removal of steric hindrance for receptor association and subsequent
EGFR activation.
3.4. Galectin-3 colocalizes with EGFR on the cell surface of EGF-induced
3T3–EGFR cells
Since the activity of Neu1 tethered to EGFR hydrolyzes α-2,3-sialyl
residues exposing terminal β-galactosides, we questioned whether
there are mammalian lectins stabilizing pEGFR. Indeed, Zhao et al. [37]
have proposed that activated EGFRs are anchored on the cell surface
by a galectin-3 lattice, leading to the positive regulation of EGFR signals.
Other reports have demonstrated that galectin-3 is a member of a large
family of beta-galactoside-binding lectins on surface glycoproteins [38],
and its expression necessitates tyrosine kinase phosphorylation [39].
Galectin-3 is characteristically localized in the cytosol but possesses
the ability to cross intracellular and plasma membranes to translocate
into the nucleus, mitochondria, cell surface or extracellular milieu
[40,41]. Confocal microscopy validated the predicted association of
galectin-3 with EGF receptors in naïve (26% overlay) and EGF-treated
(86% overlay) 3T3–hEGFR cells (Fig. 3A). To conﬁrm these results, co-
immunoprecipitation experiments using cell lysates from 3T3–EGFR
cells further validated that galectin-3 forms a complex with EGF-
stimulated receptors as expected (Fig. 3B).
3.5. Neu1 co-immunoprecipitates with EGF receptors in cell lysates of naïve
and EGF-stimulated 3T3–hEGFR cells
Since Neu1 is induced within a minute on the cell surface by EGF
treatment of live cells, we asked whether Neu1 is associated with EGF
receptors similar to what we had observed with TrkA [19] and TLR
[20,22] receptors. Co-immunoprecipitation experiments using cell ly-
sates from 3T3–hEGFR cells demonstrated that Neu1 (Fig. 4A) and not
Neu-2 nor -3 (Fig. 4B) forms a complex with naïve and EGF-
stimulated EGFRs. Although Neu4 co-immunoprecipitated with EGFR,
recent reports have indicated that Neu4 is tethered to MMP9 but
requires a special ligand to become activated [42,43]. Neu-2 and -4
were present in the whole cell lysates from naïve 3T3–hEGFR cells
(Fig. 4C). We were unable to detect Neu3 in the whole cell lysates
because the antibody weakly reacts with Neu-3.
Taken together, these results indicate that Neu1 forms a complex
with EGFR on the cell surface prior to ligand binding, which is consistent
with another previous report on EGF receptors [44]. These ﬁndings
suggest that Neu1 may be a common requisite intermediate in regulat-
ing EGF induced receptor activation.
3.6. Neu1 and matrix metalloproteinase-9 (MMP-9) cross-talk is essential
for EGF-induced EGFR activation in 3T3–hEGFR cells
If Neu1 forms a complex with EGF receptors, we questioned how
EGF binding to its receptor activates Neu1. Insight to this question
came from our previous report demonstrating that NGF binding to
TrkA potentiates GPCR-signaling via membrane Gαi subunit proteins
and MMP-9 activation to induce Neu1 in live primary neurons and
TrkA- and TrkB-expressing cell lines [19]. A similar Neu1–MMP-9
cross-talk was identiﬁed by us for TOLL-like receptors [20]. Based on
these latter ﬁndings, we asked whether Neu1 is also connected with
MMP-9 and GPCR for ligand-induced EGFRs. Indeed, other studies
have clearly demonstrated that in a series of patients with non-small-
cell lung cancer (NSCLC), the expression of EGFR did not associate
with prognosis [45] but instead, co-expression of EGFR and MMP-9
identiﬁed a subset of patients with a signiﬁcantly worse prognosis
than either EGFR or MMP-9 alone [45,46]. In addition, the in vitro
experiments have demonstrated that EGF stimulation of EGFR-positive
Fig. 3. (A) Galectin-3 colocalizes with EGFR. 3T3–hEGFR cells were treatedwith 30 ng/mL EGF for 5 min or left untreated as no ligand control. Cells were ﬁxed, permeabilized, and immu-
nostained with 4 μg/mL mouse anti-galectin-3 and 4 μg/mL rabbit anti-EGFR followed by 40 μg/mL AlexaFluor 594 conjugated with goat anti-mouse IgG antibody and 40 μg/mL
AlexaFluor 488 conjugated with goat anti-rabbit IgG. Stained cells were visualized using a confocal inverted microscope (Leica TCS SP2 MP inverted confocal microscope) with 100×
oil objective. Imageswere capturedusing a z-stage of 8–10 images/cell at 0.5-mmsteps andwere processed using Image J version 1.38× software. To calculate the amount of colocalization
in the selected images, the Pearson correlation coefﬁcient was measured and expressed as a percentage using Image J. The data are a representation of one of three independent
experiments showing similar results. (B) Galectin-3 co-immunoprecipitates with EGF-induced pEGFR. 3T3–hEGFR cells are left cultured in medium or in medium containing 30 ng/mL
EGF. Cells (1 × 107 cells) are pelleted and lysed in lysis buffer. Galectin-3 and EGFR in cell lysates are immunoprecipitated with mouse anti-galectin-3 and rabbit anti-EGFR for 24 h.
Following immunoprecipitation, immunocomplexes are isolated using protein A or G magnetic beads and resolved by 8% gel electrophoresis (SDS-PAGE). The blots are probed for
galectin-3 (31 kDa) with anti-galectin-3 or EGFR (170 kDa) with anti-EGFR antibodies followed by Clean-Blot IP Detection Reagent for immunoprecipitation/Western blots andWestern
Lightning Chemiluminescence Reagent Plus; IP, immunoprecipitation. The chemiluminescence reaction was analyzed with X-ray ﬁlm. Sample concentration for gel loading was
determined by Bradford Assay. The data are a representation of one of three independent experiments showing similar results.
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inhibition of EGFR in vivo reduced tumor cell MMP-9 expression [47,48].
These data provided evidence for the support of a co-expression of
MMP-9 and EGFR that may identify patients with activated EGFR.
Accordingly, we propose that Neu1-MMP-9 cross-talk in alliance with
GPCR is required for EGF activation of EGFR.
To test this hypothesis, the inhibitory effect of the broad range MMP
inhibitor, galardin (GM6001), neuromedin B GPCR speciﬁc antagonist
BIM-23127 and the selective inhibitor of the whole heterotrimeric G-
protein complex named BIM-46174 [49], an imidazo-pyrazine deriva-
tive, on sialidase activity associated with EGF-stimulated live 3T3–
hEGFR was examined. The data shown in Fig. 5 show that galardin
(Fig. 5A), BIM-46174 and BIM-23124 dose-dependently inhibited the
sialidase activity associated EGF-treated live 3T3–hEGFR cells compared
to the no ligand control levels. Galardin had an IC50 of 5.14 μMwhich is
comparable to an IC50 of 5.16 μM for the speciﬁc MMP9 inhibitor
(MMP9i) (Fig. 6A). For MMP3i, the IC50 was 416 mM (Fig. 6B).
Co-immunoprecipitation experiments using cell lysates from 3T3–
hEGFR cells demonstrated that MMP-9 forms a complex with naïve
and EGF-stimulated EGFRs (Fig. 6C). Western blot analyses clearly
showed that MMP9i inhibited EGF-induced pEGFR in these cell lysates
(Fig. 6D). Together, the additional intracellular and cell-surface co-
localization of Neu1 and MMP-9 validated the predicted cross-talk
between the neuromedin B GPCR–MMP-9–Neu1 tripartite complex
coupled to EGF receptors.3.7. Targeting Neu1 with Tamiﬂu impedes the tumor growth in hetero-
topic xenograft of human pancreatic MiaPaCa-2-eGFP cancer cells in
RAG2−/−xCγ−/− double mutant mice
Since the co-expression of EGFR andMMP-9 has prognostic value in
cancer [45,46], and Neu1 and MMP-9 cross-talk regulates EGFRs, we
investigated the molecular targeting potential of the Neu1–MMP9
crosstalk platform in human pancreatic cancer cell lines in vitro and
in vivo. As shown in Fig. 7A and B, EGF stimulation of live PANC-1 and
MiaPaCa-2 cells induced sialidase activity which was blocked by
Tamiﬂu, anti-Neu1 antibody and MMP-9i compared to EGF-
stimulated cells and no ligand control levels. These data are consis-
tent with the results with live 3T3–hEGFR cells and identify a novel
alternate therapeutic target for pancreatic cancer. The data shown
in Fig. 7C, indicated that Tamiﬂu treatment of these pancreatic can-
cer cell lines, reproducibly and dose-dependently abated the cell vi-
ability (percentage of untreated control) as determined by the MTT
((3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide,
yellow tetrazole) cell proliferation assay after 72 h of incubation.
The preclinical in vivo anti-tumor activity of Tamiﬂu was also inves-
tigated in a RAG2−/−/Cγ−/− double mutant xenograft mouse model of
human pancreatic cancer. The RAG2/Cγ double mutant mice lack
mature T cells, B cells, and functional NK cells, and are deﬁcient in
cytokine signaling, leading to better engraftment of human cells than
any other published mouse strain. The hypothesis is that Tamiﬂu
Fig. 4. (A) Neu1 co-immunoprecipitateswith EGFR. 3T3–hEGFR cells were treatedwith 30 ng/mL EGF for 5 min, or pretreatedwith 400 μMTamiﬂu for 30 min followed by 30 ng/mL EGF
for 5 min or left untreated as control (media). Cells were pelleted, lysed in lysis buffer and the protein lysateswere immunoprecipitated with 1 μg of goat anti-EGFR antibody overnight at
4 °C. Immunocomplexes were isolated using protein G magnetic beads, resolved by SDS-PAGE and the blot probed with rabbit anti-Neu1 antibody overnight at 4 °C followed by HRP-
conjugated goat anti-rabbit HRP-conjugated secondary antibody for 75 min at 20 °C and Western Lightning Chemiluminescence Reagent Plus. NIH3T3 and 3T3–hEGFR cells not
immunoprecipitated (no IP Ab) served as negative controls. The data are a representation of one out of four independent experiments showing similar results. (B) Neu-2 and -3 do not
co-immunoprecipitate with EGFR. 3T3–hEGFR cells were used as described in (A). (C) Western blot of unstimulated 3T3–hEGFR cells was run simultaneously with the immunoprecipi-
tation to detect levels of Neu-2, -3, and -4 proteins in the same cell lysates. The data are a representation of one out of three independent experiments showing similar results.
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this heterotopic xenograft mouse model of human pancreatic cancers.
MiaPaCa-2-eGFP pancreatic cancer cells at 1.5 × 106 cells in 0.2 mL
were implanted cutaneously in the right back ﬂank of these mice.
Twice a week, each mouse following implantation of the cancer cells
was monitored for tumor volume growth (length and width) at the
site of implantation, body weight, and body condition scoring. Scoring
the body condition of rodents is a non-invasive method for assessing
health and establishing endpoints for adults where body weight is not
a viable monitoring tool.
The data shown in Fig. 8A clearly demonstrate that 100 mg/kg of
soluble Tamiﬂu daily injection intraperitoneally in sterile saline at day
42 post-implantation when the tumor volume reached 100–200 mm3
reproducibly impeded the tumor growth rate compared to the
untreated cohort. Following Tamiﬂu treatment, there was no signiﬁcant
(p b 0.1951) increase in tumor volume in a time-to-progression growth
rate compared to the signiﬁcant (p b 0.0082) growth rate in tumor
volume for the untreated cohort. The data also shown in Fig. 8B depicts
the tumor size on the right ﬂank at day 47 post-cancer cell implantation
for the untreated and Tamiﬂu treated tumor-bearing mice. There was a
signiﬁcant reduction in tumor size (Fig. 8C) and tumor weight (Fig. 8D)
from the Tamiﬂu treated tumor-bearing mice compared to the
untreated cohort. This dose regime of Tamiﬂu had no side effects as
determined by no loss of body weight and body condition scoring(data not shown). The data shown in Fig. 8E illustrate the pictures of
the tumors at necropsy and the individual tumor histology staining
using hematoxylin and eosin stain (H&E) for the untreated and
Tamiﬂu-treated cohorts.
3.8. Western blot analyses for phosphorylated EGFR (pEGFR), pStat1, and
pNFκB in the tumor lysates
To conﬁrm the anti-cancer role of Tamiﬂu in vivo, Western blot
analyses for phosphorylated EGFR (pEGFR), pStat1, and pNFκB in the
tumor lysates were performed on individual tumors taken from the
untreated and Tamiﬂu treated cohorts. Remarkably, the data shown in
Fig. 9A indicate a signiﬁcant inhibition of pEGFR and downstream
pNFκB and pStat1 activity in the tumor lysates from Tamiﬂu treated
tumor-bearing mice compared to the untreated cohort. To further
validate the Western blot analyses, we also performed a Bio-Plex
phospho-proteinmultiplex analysis to simultaneously examine numer-
ous phosphorylation protein end-points in the tumor lysates following
Tamiﬂu therapy. As shown in Fig. 9B, the phospho-protein end-points
of Akt-Thr308, PDGFRα-Tyr754 and STAT1-Tyr701 were diminished in
the tumor lysates fromTamiﬂu treated cohort compared to the untreated
group. In contrast, Tamiﬂu treatment increased the phospho-protein
end-points of SMAD2-Ser465/467 and VEGFR2-Tyr1175 compared to
the untreated cohort.
Fig. 5. EGF-induced sialidase activity in live 3T3–hEGFR cells is inhibited by (A) galardin (GM6001) and (B) selective inhibitor of whole heterotrimeric G-protein complex BIM-46174 in a
dose-dependent manner. After removing medium, 0.2 mM 4-MUNANA substrate in Tris-buffered saline, pH 7.4, was added to cells alone (CTRL), with 30 ng/mL EGF, or with EGF in
combination with galardin, BIM-46174 or BIM-23127 (neuromedin B GPCR speciﬁc antagonist) at the indicated concentrations. Fluorescent images were taken at 1 min after adding
substrate using epi-ﬂuorescent microscopy (40× objective). The IC50 of galardin was determined by plotting the decrease in sialidase activity against the log of the agent concentration.
The data are a representation of one of four independent experiments showing similar results.
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creatic MiaPaCa-2-eGFP cancer cells in heterotopic xenograft of tumors in
RAG2−/−xCγ−/− double mutant mice
Biophotonic images of live necropsy tissues of tumor (a), liver (b),
lung (c), spleen (d) and heart (e) as depicted in Fig. 10A clearly indicate
that the daily dosage of 100 mg/kg Tamiﬂu injected intraperitoneally
attenuated metastatic spread of MiaPaCa-2-eGFP cells to the liver
(Fig. 10B) and lung (Fig. 11A) compared to the untreated cohort. This
lack of metastatic spread to these tissues may be due to a reduction in
the tumor vascularization (see Fig. 8E). The H&E staining of microtone
sections of the liver (Fig. 10B) and lung (Fig. 11A) necropsy tissues
taken from each mouse in the untreated and Tamiﬂu treated cohorts
conﬁrms the biophotonic image results. It is noteworthy that there
were no visible liver tumor nodules except for one lung tissue. Histology
analysis of the H&E staining for liver (Fig. 10C) and lung (Fig. 11B)
metastatic clusters (visible 10–50 metastatic cells) or nodules indicate
that Tamiﬂu treated cohort had fewer metastatic cells than the
untreated cohort. These ﬁndings support the premise that Tamiﬂu ther-
apy has potential anti-tumor and anti-metastatic properties in vivowith
no side-effects on the health of the animals.
4. Discussion
The molecular mechanism(s) by which EGFRs become activated are
not well understood. There is substantial evidence to indicate that EGFR
dimerization is an essential required step in the receptor activation
mechanism [2–8]. However, the parameters controlling interactions
between the receptors and their ligands to facilitate receptor dimeriza-
tion remained poorly deﬁned until now. The ﬁndings in this report un-
cover amolecular organizational signaling platform of a novel Neu1 and
MMP-9 cross-talk in alliance with EGF receptors on the cell surface ofEGFR-expressing cells as well as human pancreatic MiaPaCa-2 and
PANC-1 cancer cells that is essential for EGF activation of EGFRs and
subsequent cellular signaling. At the genetic level, the sialidase activity
associated with EGF stimulation of human 1140F01 and WG0544 type
1 sialidosis ﬁbroblast cell lines was completely abrogated. These
sialidosis ﬁbroblast cells were obtained from patients with type 1
sialidosis or mucolipidosis-1 who have a true Neu1 deﬁciency [16].
Our preclinical studies focused on directly targeting and inhibiting
Neu1 as the key central enzyme within this receptor signaling platform
provide the proof-of-evidence for an alternate targeted therapy in the
treatment of human pancreatic cancer growth and metastatic spread
in heterotopic xenograft of tumors growing in RAG2−/−xCγ−/− double
mutant mice. The ﬁndings identify for the ﬁrst time that Neu1 sialidase
may be a novel cancer-targeting enzyme using a new utility application
of an existing, commonly prescribed human drug, Tamiﬂu.
Research in cancer treatment has looked at ways to modulate cellu-
lar pathways that are essential for cancer to survive and grow [1].
Numerous receptors and molecular pathways have been implicated in
oncogenesis, cancer growth and proliferation including Ras, EGFR,
VEGF, gastrin and matrix metalloproteinases (zinc-dependent endo-
peptidases). Several of the growth factors and their receptor tyrosine
kinase (RTK) are overexpressed during the progression of pancreatic
cancer. It follows that RTKs are promising candidate targets for cancer
therapy and has led to the development of the RTK tyrosine kinase
inhibitors. Despite the dramatic initial responses to these inhibitors,
most patients ultimately develop drug resistance and relapse. For exam-
ple, the mutational expression of the EGF receptors in cancer cells has
been identiﬁed in a variety of human tumors, including lung, breast,
head and neck, ovarian and pancreatic cancers [50,51]. These altered
EGFRs have been reported to promote cell survival, proliferation, inva-
sion, andmetastasis through activation of JAK/STAT (Janus kinase/signal
transducers and activators of transcription), PI3K (phosphoinositol 3-
Fig. 6. (A) SpeciﬁcMMP-9 inhibitor blocks dose-dependently EGF-induced sialidase activity in live 3T3–hEGFR cells, but not by (B) speciﬁcMMP-3 inhibitor. EGF-induced sialidase activity
in live 3T3–hEGFR cellswasmeasured as described in Fig. 1A. Cellswere treatedwith 30 ng/mL EGF, in combinationwith speciﬁcMMP9i or speciﬁcMMP3i at the indicated concentrations
or left untreated as control. Fluorescent imageswere taken at 2 min after adding 4-MUNANA substrate using epi-ﬂuorescentmicroscopy (10× objective). The IC50 of MMP-9i andMMP-3i
was determined byplotting the decrease in sialidase activity against the log of the agent concentration. Thedata are a representation of one out of three independent experiments showing
similar results. (C) MMP9 co-immunoprecipitates with EGFR. 3T3–hEGFR cells were treated with 30 ng/mL EGF for 5 min, or pretreated with 400 μM Tamiﬂu for 30 min followed by
30 ng/mL EGF for 5 min or left untreated as control (media). Cells were pelleted, lysed in lysis buffer and the protein lysates were immunoprecipitated with 1 μg of goat anti-EGFR anti-
body overnight at 4 °C. Immunocomplexes were isolated using protein G magnetic beads, resolved by SDS-PAGE and the blot probed with rabbit anti-MMP-9 antibody overnight at 4 °C
followed by HRP-conjugated goat anti-rabbit HRP-conjugated secondary antibody for 75 min at 20 °C and Western Lightning Chemiluminescence Reagent Plus. 3T3–hEGFR cells not
immunoprecipitated (no IP Ab) served as negative controls. The data are a representation of one out of three independent experiments showing similar results. (D)Western blot analyses
of MMP9i on EGF-induced EGFR phosphorylation in 3T3–hEGFR cells. Cells were left untreated (control), stimulated with 30 ng/mL EGF for 5 min, or pretreated with 50 μg/mL or 75 μg/mL
MMP9i for 30 min followed by 30 ng/mL EGF. Unstimulated NIH3T3 cells were added as an EGFR negative control. Cells were pelleted, lysed in lysis buffer and the cell lysates were resolved
by SDS-PAGE. The blot was probed with 0.14 μg/mL rabbit anti-human pEGFR antibody overnight at 4 °C followed by 40 ng/mL horse radish peroxidase-labeled goat anti-rabbit antibody for
75 min at 20 °C andWestern Lightning Chemiluminescence Reagent Plus for 5 min. After development, blots were stripped and reprobedwith rabbit anti-pan hEGFR as a loading control. The
data are a representation of one out of three independent experiments showing similar results.
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pathways [51–53]. Over 50% of tumor resistance is caused by amutation
in the ATP binding pocket of the EGFR kinase domain involving substi-
tution of a small polar threonine residue with a large nonpolar methio-
nine residue (T790M) [54]. Other causes of drug resistance can involve
(a) ampliﬁcation of the hepatocyte growth factor receptor, which drives
ERBB3 dependent activation of PI3K [55,56], (b) numerous mutations,
including recruitment of a mutated insulin growth factor-1 (IGF-1)
receptor to dimerizewith EGFR in forming a heterodimer [57], allowing
activation of the downstream effectors of EGFR even in the presence of
an EGFR inhibitor, and (c) inactivating mutations of the PTEN tumor
suppressor, which allow increased activation of Akt independent of
stimulation by EGFR [58]. For an ideal clinically relevant effect to be
achieved, therapeutic strategies must target and inhibit several
oncogenic pathways at the same time, or at multiple levels of a major
pathway [1]. It is essential in the clinical settings that these targeted
therapies are to circumvent the genetic mutations at different growth
receptor levels to resistance, tumor neovascularization, the chemo-
resistance potential of tumors and the development of metastases.
The ﬁndings in this report propose an alternate therapeutic
approach using Tamiﬂu as an exciting new anti-cancer agent targetingNeu1 sialidase. We have reported that Neu1 acts through a receptor
level signaling pathway on the cell surface to modulate a number of
glycosylated receptors [59] such as EGFR in this report, TrkA [19], and
TOLL-like receptors [18,20,22,60,61]; these receptors are known to
play major roles in cancer. Indeed, other reports have provided
supporting evidence for a role of Neu1 in the receptor glycosylation
modiﬁcation model in respiratory airway epithelia. Goldblum and col-
leagues have demonstrated that Neu1 associateswith EGFR and cell sur-
face associated mucin-1 (MUC1) in respiratory airway epithelial cells,
and that this Neu1-EGFR association was regulated by EGF stimulation
[44]. In addition, they found that EGF receptors are substrates for
Neu1 in vivo, and thus have proposed that Neu1 expression in airway
epithelial repair and wound healing, tumorigenesis, and metastatic po-
tential. Indeed, others have shown that when overly expressed Neu1 in
colon cancer HT29 cells were injected trans-splenically into mice, the
liver metastasis was signiﬁcantly reduced [62]. To explain these latter
results, the over-expression of Neu1 would desialylate the terminally
sialylated N-linked oligosaccharides to which ganglioside GM3 binds
at the ectodomain of EGFR, and thereby promoting the GM3–EGFR in-
teraction and attenuation of EGFR activation [44]. The inhibitory modu-
lation of EGF receptor activity by changes in the GM3 content in
Fig. 7. EGF-induced sialidase activity in live human pancreatic epithelial carcinoma PANC-1 (A) andMiaPaCa-2 (B) cell lines is blocked by Tamiﬂu, anti-Neu1 andMMP-9 inhibitor (MMP-
9i). Cells were allowed to adhere on 12 mm circular glass slides in media containing 10% fetal calf sera for 24 h. After removing media, 0.318 mM 4-MUNANA (4-MU) substrate (2′-(4-
methlyumbelliferyl)-α-N-acetylneuraminic acid) in Tris buffered saline pH 7.4 was added to live untreated cells alone (control) or with 30 ng/mL EGF alone and in combination with
400 μM Tamiﬂu, 100 μg/mL anti-Neu1 neutralizing antibodies, and 50 μg/mL MMP9i. Fluorescent images were taken at 2 min after adding substrate using epi-ﬂuorescent microscopy
(40× objective). Themean ﬂuorescence of 50multi-point replicateswas quantiﬁed using the Image J software. The data are a representation of one out of three independent experiments
showing similar results. (C) Cell viability PANC-1 andMiaPaCa-2 cells treatedwith Tamiﬂu at different doses using theMTT assay. Cells were incubated in 96 well plates (5000 cells/well)
and allowed to adhere for 24 h in 1× DMEMmedia containing 10% FCS. The media were replaced with fresh DMEMmedia containing 5% FCS without or with various concentrations of
Tamiﬂu for 72 h as predetermined optimally. Cell viability as a percent of control ± S.E. of triplicate values was determined using the MTT assay. Staurosporine at 2 μM was used as a
positive control for cell death. The data are a representation of one out of three independent experiments showing similar results.
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expressed Neu1 in colon cancer HT29 cells was proposed to actively
desialylate the integrin β4 protein, the process of which abrogated its
role in metastasis [62]. Others have shown that a stable transfection of
a gene encoding a soluble Mr 42,000 sialidase into a human epidermoid
carcinoma cell line did not modify the binding of EGF to its receptor but
enhanced EGFR tyrosine autophosphorylation and diminished the level
of ganglioside GM3 [70].
The novel molecular cancer-targeting role for Neu1 is based on
the ﬁndings that Neu1 and MMP-9 are already in complex with
naïve EGFRs, and are rapidly induced upon EGF stimulation. Acti-
vated Neu1 speciﬁcally hydrolyzes α-2,3-sialyl residues linked to
β-galactoside, which are distant from ligand binding, enabling removal
of steric hindrance to receptor association, and subsequent signaling
pathways. These latter results are consistent with our previous reports
[19,20,22,60,61]. The ﬁndings in this report also provide evidence for
MMP-9 involvement in the ligand activation of EGFR. We have reported
that Neu1 in alliance with GPCR-signaling Gαi subunit proteins and
MMP-9 is expressed on the cell surface of TrkA- [19] and TLR- [20]
expressing cells. This tripartite alliance makes Neu1 readily available to
be induced by ligand binding to the receptor. Our data support thispremise. How Neu1 sialidase is rapidly induced by MMP-9 together
with GPCR Gαi subunit proteins still remains unknown. It can be specu-
lated that EGF binding to EGFR on the cell surface initiates GPCR-signaling
via GPCR Gα subunit proteins to activate MMP-9. Our data using speciﬁc
inhibitors of GPCR suggest that the neuromedin B GPCR is associatedwith
EGF-induced sialidase activity in live 3T3–hEGFR cells (see Fig. 5B). In-
deed, Moody et al. [71] have reported that the neuromedin B GPCR regu-
lates EGF receptor transactivation by a mechanism dependent on Src as
well as MMP activation. It is well known that agonist-bound GPCRs
have been shown to activate numerous MMPs [72], including MMP-3
[73], MMPs 2 and 9 [74,75], including the members of the ADAM
family of metalloproteinases [76,77]. We have shown that GPCR ag-
onists can directly activate Neu1 through the intermediate MMP-9
in order to induce transactivation of TOLL-like receptors and subse-
quent cellular signaling [60]. It is noteworthy that others have
found a dramatic increase in the activity of MMP-9 in gemcitabine-
resistant pancreatic cancer cells [78], which ﬁts well within our mo-
lecular signaling platform of Neu1–MMP-9 cross-talk in regulating
ligand-induced EGFRs.
If Neu1 sialidase is playing a major role in the activation of EGFR as
our data suggest, logistically Neu1 has the potential to be an alternative
Fig. 8. Tamiﬂu treatment at 100 mg/kg (i.p.) impedes humanpancreaticMiaPaCa-2-eGFP cancer cell growth in heterotopic xenograft of tumors growing in RAG−/−xCγ−/− doublemutant
mice. (A) MiaPaCa-2-eGFP cells at 1.5 × 106 in 0.2 mL were implanted cutaneously in the right back ﬂank of these mice. Twice a week following implantation of the cancer cells each
mouse was monitored for tumor volume (length and width) at the site of implantation, body weights and body condition scoring. Mice were treated with 100 mg/kg Tamiﬂu in sterile
saline intraperitoneally at day 42 post-implantation when the tumor volume reached approximately 100–200 mm3. Mice were sacriﬁced at day 47 post-implantation. The p value is
the probability from one-way ANOVA of the time-to-tumor progression associated tumor growth pattern occurring by chance. (B) Representative tumor on the right ﬂank of the animal.
(C) Necropsy tumor size in length and (D) tumor weight, mean ± S.E., taken from each mouse at day 47 endpoint post-implantation. (E) Necropsy tumors and H&E staining of tumors
from untreated and Tamiﬂu-treated cohorts.
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MiaPaCa-2 and PANC-1 pancreatic cancer cell lines in culture dose-
dependently diminished the cell viability with time. We also observed
that Tamiﬂu treatment of these pancreatic cancer cell lines blocked
Neu1 activity associated with EGF-stimulation of PANC-1 and
MiaPaCa-2 cell lines. Based on these observations, we proposed that
Neu1 might be an alternate candidate target using a commonly
prescribed anti-viral drug Tamiﬂu in restraining the growth and spread
of human pancreatic cancer.
To test this hypothesis, the preclinical data in this report provide for
the ﬁrst time the proof-of-evidence that Tamiﬂu can impede pancreatic
tumor growth and spread in vivo. The in vivo anti-tumor activity of
Tamiﬂu was investigated in a RAG2−/−xCγ−/− double mutant
xenograft mouse model of human pancreatic cancer. Tamiﬂu therapy
at 100 mg/kg daily dosage intraperitoneally expectedly impeded
human pancreatic tumor growth in a time-to-progression growth rate
compared to the untreated cohort. Following Tamiﬂu treatment, there
was no signiﬁcant increase in the time-to-progression tumor growth
rate compared to a signiﬁcant tumor growth rate for the untreated
cohort. To conﬁrm these results, we also found at necropsy that there
was a signiﬁcant reduction in tumor size and tumor weights at day 47
post-implantation taken from the Tamiﬂu treated tumor-bearing mice
compared to the untreated cohort. This dose regime of Tamiﬂu had no
side effects as determined by body weight and body condition scoring
(data not shown).To further conﬁrm the in vivo efﬁcacy of Tamiﬂu therapy, the proﬁles
of multiple phosphorylated proteins in the tumor lysates involved in
cell signaling pathways were investigated using Western blot analyses
and the Bio-Plex multiplex format to detect the proﬁles of multiple
phosphorylated proteins in a single tumor sample lysate. This latter
assay protocol is based on 6.5 μmmagnetic beads which are optimized
for high sensitivity and higher speciﬁcity in minimizing cross-reactivity
with broad dynamic range using highly speciﬁc antibodies. Individual
tumors taken from the Tamiﬂu treated cohorts expressed a signiﬁcant
less phosphorylation of EGFR-Tyr1173, Stat1-Tyr701, and NFκBp65-
Ser311 compared to the untreated cohort as determined by Western
blot analyses (Fig. 8A). The Bio-Plex multiplex format also showed a
reduction in phosphorylation of Akt-Thr308, PDGFRα-Tyr754 and
STAT1-Tyr701, but unexpectedly, an increased in phospho-Smad2-
Ser465/467 and phospho-VEGFR2-Tyr1175 in the tumor lysates from
the Tamiﬂu treated cohort compared to the untreated cohort (Fig. 8B).
To explain these latter ﬁndings, it is noteworthy that Smad2 has been
reported to function as a tumor suppressor of prostate [79] and breast
[80] epithelial cancer cells as well as epithelial to mesenchymal transi-
tion (EMT) during skin cancer formation and progression [81,82]. The
Smad signal integration in epithelial cell plasticity is eloquently
reviewed by Sundqvist et al. [83] and Miyazono et al. [84]. For the
increased phospho-VEGFR2-Tyr1175 expression in tumor lysates from
Tamiﬂu-treated cohorts, others have found that prolonged VEGF signal-
ing in the absence of endothelial epsins 1 and 2 produces leaky,
Fig. 9. Tamiﬂu treatment at 100 mg/kg (i.p.) attenuates pEGFR and pNFκB activity in heterotopic xenografts of MiaPaCa-2-eGFP tumors growing in RAG−/−xCγ−/− double mutant mice.
(A) Individual necropsy tumors were taken from untreated and 100 mg/kg Tamiﬂu treated cohorts described in Fig. 8. Freshly frozen tumors were thawed on ice, and lysed in lysis buffer
containing proteinase and phosphatase inhibitors. The tumor lysateswere resolved by SDS-PAGE. The blotwas probedwith 0.14 μg/mL rabbit anti-humanpEGFR antibody, 1 μg/mL rabbit
anti-NFκBp65 Ser(P)311 antibody or 2 μg/mL rabbit anti-Stat1 p84/p91 antibody overnight at 4 °C followed by 0.04 μg/mL horse radish peroxidase-labeled goat anti-rabbit antibody for
75 min at 20 °C andWestern LightningChemiluminescence Reagent Plus for 5 min. After development, blotswere stripped and reprobedwith rabbit anti-β actin as a loading control. Each
lane represents a single tumor lysate from a numbered mouse. Quantitative analysis was done by assessing the density of a band corrected for background in each lane using Corel Photo
Paint 8.0 software. Each bar in the graphs represents themean ratio ofNFκBp65Ser(P)311, pSTAT1 or pEGFR toβ-actin of banddensity ± S.E. (error bars) for untreated andTamiﬂu treated
cohorts. p values represent signiﬁcant differences at 95% conﬁdence using theDunnettmultiple comparison test comparedwith untreated cohort for the indicated tumornumbers. (B) Bio-
Plex magnetic beads of indicated phospho-proteins were used to measure the phospho-protein content in each of same tumor lysate used in (A) according to Bio-Plex protocol and Bio-
Plex 200 System analyzer. The data are expressed as mean ﬂuorescence intensity (MFI). The phosphatase-treated control is a standard negative control provided in the assay kit.
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retardation [85]. The epsins are a family of ubiquitin-binding endocytic
clathrin adaptor proteins. They found that epsins-1 and -2 knockout
mice exhibited highly disorganized vascular structures with increased
vascular permeability in tumors, which was due to an increased
VEGFR2 signaling, an increased non-productive tumor angiogenesis
and a retarded tumor growth [85]. VEGF binding VEGFR2 promotes
epsin binding to ubiquitinated VEGFR2 to facilitate endocytosis and
degradation of VEGFR2. It was proposed that epsins 1 and 2might func-
tion as unique attenuators of VEGF signaling [85]. Indeed, tumor vascu-
lature requires stringently balanced VEGF signaling to provide sufﬁcient
productive angiogenesis for tumor development. The ﬁndings in this
report indicate that Tamiﬂu treatment of tumor-bearing mice may
have disrupted tumor vasculature (Fig. 7E), perhaps by blocking epsins
via an unknown mechanism. Our data suggest a potential anti-
angiogenic strategy by which Tamiﬂu treatment of tumor-bearing
mice may down-regulate endothelial epsins 1 and 2 functions andpromote local excessive VEGF signaling. This novel pro-VEGFR2 and
pro-Smad2 signaling as a consequence of Tamiﬂu therapy proposes
another anti-cancer role for Tamiﬂu that has an uncharacterized proper-
ty with broader speciﬁcities than expected.
Live necropsy tissues of lung, liver, heart, spleen and intestine were
all found normal following the dosage regime of Tamiﬂu. In addition,
the data indicated that the daily dosage of 100 mg/kg Tamiﬂu intraper-
itoneally also attenuated metastatic spread of MiaPaCa-2-eGFP cells to
the liver and lung compared to the biophotonic images from the
untreated cohort. This lack of metastatic spread to the liver and lung
following Tamiﬂu treatment may be due to a reduction in the tumor
neovascularization as shown in Fig. 8E. The H&E staining of microtone
sections of liver (Fig. 10B) and lung (Fig. 11A) necropsy tissues
conﬁrmed the biophotonic image results. These ﬁndings support the
premise that Tamiﬂu therapy has promising anti-tumor proliferative
properties, anti-tumor vascularization and anti-metastatic spread,
in vivo.
Fig. 10. (A) Biophotonic images of live necropsy a—tumor, b—liver, c—lung, d—spleen and e—heart, and (B) H&E staining of liver from untreated, Tamiﬂu-treated cohorts and liver tissue
from normal mice. (C) Number of metastatic clusters per liver.
2601A.M. Gilmour et al. / Cellular Signalling 25 (2013) 2587–2603The proof-of-mechanism of this novel anti-cancer role of Tamiﬂu is
that it is an inhibitor of Neu1which acts through a receptor level signal-
ing pathway on the cell surface to modulate a number of glycosylated
receptors such as EGFR in this report, TrkA [19], insulin (unpublishedFig. 11. (A) H&E staining of lung from untreated, Tamiﬂu-treated cohorts and ldata) and TOLL-like [20] receptors, all of which play important roles in
tumorigenesis. It follows that the therapeutic efﬁcacy of Tamiﬂu
targeting Neu1 tethered to these receptors would be stringently dose-
dependent. We propose here that Tamiﬂu treatment strategies be inung tissue from normal mice. (B) Number of metastatic clusters per lung.
2602 A.M. Gilmour et al. / Cellular Signalling 25 (2013) 2587–2603the form of a horizontal approach, of which several important cancer
growth factor receptor signaling platforms, oncogenic pathways and
macrophage-mediated tumor progressions are targetedwith promising
therapeutic intent.
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